We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Secukinumab 300 mg administered with an auto-injector ...

Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with secukinumab, which selectively ...

STEPIn enrolled systemic- and phototherapy-naïve adults with plaque psoriasis ≤1 year and randomized secukinumab 300 mg versus nb-UVB for 52 weeks, then observed off-treatment to week 104. Off-therapy ...

Secukinumab achieved complete symptom resolution in patients with pediatric generalized pustular psoriasis (GPP) by week 2, with sustained improvements through week 70. The treatment regimen was ...

More patients with recently diagnosed psoriatic arthritis (PsA) saw clinical improvement by 3 months in a treat-to-target strategy with secukinumab, a monoclonal antibody targeting interleukin-17, ...